238 related articles for article (PubMed ID: 26140610)
1. Tocilizumab for steroid refractory acute graft-versus-host disease.
Roddy JV; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC; Benson DM; Andritsos LA; Devine SM; Efebera YA
Leuk Lymphoma; 2016; 57(1):81-5. PubMed ID: 26140610
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
3. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract.
Ganetsky A; Frey NV; Hexner EO; Loren AW; Gill SI; Luger SM; Mangan JK; Martin ME; Babushok DV; Drobyski WR; Smith J; Timlin C; Freyer CW; Stadtmauer EA; Porter DL
Bone Marrow Transplant; 2019 Feb; 54(2):212-217. PubMed ID: 29795429
[TBL] [Abstract][Full Text] [Related]
5. Effective use of tocilizumab for the treatment of steroid-refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin-6.
Kolb M; Bhatia M; Madina GG; Satwani P
Pediatr Blood Cancer; 2015 Feb; 62(2):362-363. PubMed ID: 25212196
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
Drobyski WR; Pasquini M; Kovatovic K; Palmer J; Douglas Rizzo J; Saad A; Saber W; Hari P
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1862-8. PubMed ID: 21745454
[TBL] [Abstract][Full Text] [Related]
8. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
9. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
[TBL] [Abstract][Full Text] [Related]
10. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study on recombinant humanized anti-CD25 monoclonal antibody used for treating steroid-resistant acute graft versus host disease following allo-hematopoietic stem cell transplantation].
Li XH; Gao CJ; DA WM; Cao YB; Xu LX; Wu YM; Liu B; Liu ZY; Yan B; Li SW; Yang XL; Wu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1535-40. PubMed ID: 24370044
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
13. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease.
Yalniz FF; Hefazi M; McCullough K; Litzow MR; Hogan WJ; Wolf R; Alkhateeb H; Kansagra A; Damlaj M; Patnaik MM
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1478-1484. PubMed ID: 28495641
[TBL] [Abstract][Full Text] [Related]
15. Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience.
De Jong CN; Saes L; Klerk CPW; Van der Klift M; Cornelissen JJ; Broers AEC
PLoS One; 2017; 12(10):e0187184. PubMed ID: 29073260
[TBL] [Abstract][Full Text] [Related]
16. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
[TBL] [Abstract][Full Text] [Related]
18. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
Khandelwal P; Lawrence J; Filipovich AH; Davies SM; Bleesing JJ; Jordan MB; Mehta P; Jodele S; Grimley MS; Kumar A; Myers K; Marsh RA
Pediatr Transplant; 2014 Feb; 18(1):94-102. PubMed ID: 24384050
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
[TBL] [Abstract][Full Text] [Related]
20. [Humanized anti-CD25 monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation].
Wu YX; Wu DP; Ma X; Jiang SS; Hou MJ; Jing YT; Liu B; Li Q; Wang X; Wu YB; Hu XH
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):755-761. PubMed ID: 38049320
[No Abstract] [Full Text] [Related]
[Next] [New Search]